Cardiff Oncology, Inc. (CRDF)

Cardiff Oncology, Inc.'s stock price has been impacted by several events over the past six months. The share price experienced a significant decline of 50.64% from March 31, 2025, to March 27, 2026. A leadership shakeup in January 2026, involving the resignation of the CEO and CFO, led to a 35% drop in shares. In February 2026, the company reported positive full-year 2025 results and a positive update from the Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC. In November 2025, positive data was announced from the ongoing Phase 2 CRDF-004 trial. In July 2025, the initial readout of the randomized Phase 2 CRDF-004 trial in first-line colorectal cancer led to a significant market reaction, with the stock falling by approximately 50%. Earnings reports for Q4 2025, Q3 2025, and Q2 2025 were reported on February 24, 2026, November 6, 2025, and July 29, 2025, respectively. Cardiff Oncology participated in several investor conferences.

Cardiff Oncology, Inc. does not currently have commercialized products or services, and its value depends on the successful development and regulatory approval of onvansertib. Therefore, there is no discernible demand seasonality for Cardiff Oncology's products or services at this time. The concept of "CRDF Seasonality" refers to historical stock price patterns, not product demand.

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies using Polo-like Kinase 1 (PLK1) inhibition. Their primary focus is advancing onvansertib, a selective PLK1 inhibitor, through clinical trials for various cancer indications, including RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple-negative breast cancer, and Chronic Myelomonocytic Leukemia.

Cardiff Oncology, Inc. currently operates only in the United States.

Cardiff Oncology's brand reputation has been influenced by positive clinical developments and corporate changes. Analyst ratings generally reflect a positive outlook, with a consensus of "Moderate Buy" or "Strong Buy". The resignation of the CEO and CFO in January 2026 led to a stock price drop, indicating investor concern. The market reaction to CRDF-004 data in July 2025 resulted in a stock decline, suggesting that investor expectations might have been higher.

Cardiff Oncology, Inc. has a mixed ownership structure including institutional, retail, and individual investors. As of March 30, 2026, there were 113 institutional owners and shareholders holding 27,318,707 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Pfizer Inc. Institutional investors own approximately 20.93% to 40.58% of the stock, insiders own around 3.87% to 4.17%, and individual investors hold a significant portion, with some reports indicating up to 60% ownership.